Pharmacokinetics and distribution of liposomal busulfan in the rat: A new formulation for intravenous administration

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 6, 1998, Pages 471-478

  Hassan, Moustapha ^a   Hassan, Zuzana ^a   Nilsson, Christina ^a   Rehim, Mohamed Abdel ^b   Kumlien, Susanne ^a   Elfsson, Birgitta ^a   Kållberg, Nils ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bioavailability; Bone marrow transplantation; Busulfan; Liposomes; Pharmacokinetics

Indexed keywords

BUSULFAN; LIPOSOME;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG TISSUE LEVEL; ENCAPSULATION; INTRAVENOUS DRUG ADMINISTRATION; LAMELLAR BODY; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BUSULFAN; CARBON RADIOISOTOPES; DRUG CARRIERS; HALF-LIFE; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0031682636     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050847     Document Type: Article

References (47)

1. Beelen DW, Quabeck K, Graeven U, Sayer HG, Mahmoud HK, Schaefer UW (1989) Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia [see comments]. Blood 74: 1507
2. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS (1996) Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 37: 401
3. Blazar BR, Ramsay NK, Kersey JH, Krivit W, Arthur DC, Filipovich AH (1985) Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Assessment of engraftment following histocompatible allogeneic bone marrow transplantation. Transplantation 39: 597
4. Chattergoon DS, Saunders EF, Klein J, Calderwood S, Doyle J, Freedman MH, Koren G (1997) An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant 20: 347
5. Coker RJ, Viviani M, Gazzard BG, Du Pont B, Pohle HD, Murphy SM, Atouguia J, Champalimaud JL, Harris JR (1993) Treatment of cryptococcosis with liposomal amphotericin B (Ambisome) in 23 patients with AIDS. AIDS 7: 829
6. Ehninger G, Schuler U, Renner U, Ehrsam M, Zeller KP, Blanz J. Storb R, Deeg HJ (1995) Use of a water-soluble busulfan formulation - pharmacokinetic studies in a canine model. Blood 85: 3247
7. Fielding RM (1991) Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clin Pharmacokinet 21: 155
8. 3H] methotrexate injected into normal or arthritic rabbit joints. J Pharm Pharmacol 40: 464
9. Geller RB, Saral R, Piantadosi S, Zahurak M, Vogelsang GB, Wingard JR, Ambinder RF, Beschorner WB, Braine HG, Burns WH (1989) Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 73: 2209
10. Gregoriadis G (1989) Liposomes as carriers of drugs. Observations on vesicle fate after injection and its control. Subcell Biochem 14: 363
11. Grochow LB (1993) Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20: 18
12. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, Santos GW, Colvin OM (1989) Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25: 55
13. Hassan M, Ehrsson H (1983) Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr 277: 374
14. 14C-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokinet 12: 71
15. Hassan M, Ehrsson H, Smedmyr B. Totterman T, Wallin I, Oberg G, Simonsson B (1989) Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant 4: 113
16. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, Totterman T, Eksborg S, Simonsson B (1989) Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 36: 525
17. Hassan M, Oberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, Lonnerholm G, Smedmyr B, Taube A, Wallin I (1991) Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28: 130
18. 11C]-busulfan in the cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol 30: 81
19. Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, Stary J, Wallin I, Kallberg N (1994) Busulfan bioavailability. Blood 84: 2144
20. Hassan M, Fasth A, Gerritsen B, Haraldsson A, Syruckova Z, Berg H, van den Sandstrom M, Karisson M, Kumlien S, Vossen J (1996) Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 18: 843
21. Hay RJ (1994) Liposomal amphotericin B. Ambisome. J Infect 28 [Suppl 1]: 35
22. Kennedy GL Jr, Sherman H (1986) Acute and subchronic toxicity of dimethylformamide and dimethylacetamide following various routes of administration. Drug Chem Toxicol 9: 147
23. Kim MM, Lee SH, Lee MG, Hwang SJ, Kim CK (1995) Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotreaxte-bearing positively charged liposomes to rats. Biopharm Drug Dispos 16: 279
24. Kim S, Kim DJ, Howell SB (1987) Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes. Cancer Chemother Pharmacol 19: 307
25. Kinney LA, Burgees BA, Stula EF, Kennedy GL Jr (1993) Inhalation studies in rates exposed to dimethylacetamide (DMAC) from 3 to 12 hours per day. Drug Chem Toxicol 16: 175
26. Lu C, Braine HG, Kaizer H, Saral R, Tutschka PJ, Santos GW (1984) Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat Rep 68: 711
27. Malley LA, Slone TW Jr, Makovec GT, Elliott GS, Kennedy GL Jr (1995) Chronic toxicity/oncogenicity of dimethylacetamide in rats and mice following inhalation exposure. Fundam Appl Toxicol 28: 80
28. Martell RW, Sher C, Jacos P, Monteagudo F (1987) High-dose busulfan and myoclonic epilepsy (letter). Ann Intern Med 106: 173
29. Martino M, Morabito F, Messina G, Irrera G, Pucci G, lacopino P (1996) Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Haematologica 81: 59
30. Mayer LD, St-Onge G (1995) Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Anal Biochem 232: 149
31. Ratanatharathorn V, Karanes C, Uberti J, Lum LG, Planque MM de, Schultz KR, Cronin S, Dan ME, Mohamed A, Hussein M (1993) Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81: 2194
32. Regazzi MB, Locatelli F, Buggia I, Bonetti F, Zecca M, Pregnolato M, Quaglini S (1993) Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation. Clin Pharmacol Ther 54: 45
33. Sanders JE (1991) The impact of marrow transplant preparative regimens on subsequent growth and development. The Seattle Marrow Transplant Team. Semin Hematol 28: 244
34. Santos GW (1989) Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation. Bone Marrow Transplant 4 [Suppl I]: 236
35. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309: 1347
36. Schuler U, Schroer S, Kuhnle A, Blanz J, Mewes K, Kumbier I, Proksch B, Zeller KP, Ehninger G (1994) Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 14: 759
37. Shaw PJ, Hugh-Jones K, Hobbs JR, Downie CJ, Barnes R (1986) Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplant 1: 193
38. Shaw PJ, Scharping CE, Brain RJ, Earl JW (1994) Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 84: 2357
39. Shulman HM, Hinterberger W (1992) Hepatic veno-occlusive disease liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 10: 197
40. Sperling S, Larsen IG (1979) Toxicity of dimethylsulfoxide (DMSO) to human corneal endothelium in vitro. Acta Ophthalmol (Copenh) 57: 891
41. Steerenberg PA, Storm G, Groot G de, Claessen A, Bergers JJ, Franken MA, Hoesel QG van, Wubs KL, Jong WH de (1988) Liposomes as drug carrier system for cis-diamminedichloroplatinum(II). II Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution. Cancer Chemothcr Pharmacol 21: 299
42. Sureda A, Perez de Oteyza J, Garcia Larana J, Odriozola J (1989) High-dose busulfan and seizures (letter). Ann Intern Med 111: 543
43. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, Brugieres L, Kalifa C, Gouyette A, Lemerle J (1990) Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 50: 6203
44. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 79: 2475
45. Vassal G, Fischer A, Challine D, Boland I, Ledheist F, Lemerle S, Vilmer E, Rahimy C, Souillet G, Gluckman E (1993) Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 82: 1030
46. Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB (1992) Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 80:2425
47. Yellowlees P, Greenfield C, McIntyre N (1980) Dimethylsulphoxide-induced toxicity. Lancet II: 1004